See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
US Politics
Republican Party
Democratic Party
Tariffs
Donald Trump
Senate
US Economy
Tesla
Elon Musk
Stock Markets
White House
Social Media
Published • loading... • Updated

Gut-liver modulator shows promising type 2 diabetes control in phase 2 clinical trial

Summary by Medical Xpress
Researchers across 14 medical centers in China, including Peking University People's Hospital, have found that an investigational drug, berberine ursodeoxycholate (HTD1801), significantly lowered blood sugar levels and improved metabolic and liver health in patients with type 2 diabetes (T2D). The findings and an invited commentary, both published in JAMA Network Open, suggest that HTD1801 could serve as a new oral treatment option for T2D and i…

5 Articles

All
Left
Center
Right
prwire.com.auprwire.com.au

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open

Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters- The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities- T2DM phase 3 data readout is expected to be announced in the first half of 2025 …

Read Full Article
dirhongkong.comdirhongkong.com

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open – DIR HONGKONG

– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters – The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities – T2DM phase 3 data readout is expected to be announced in the first half of 2…

Read Full Article
eastmud.comeastmud.com

HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open – EastMud

– Data from the proof-of-concept study showed berberine ursodeoxycholate was generally well tolerated and had beneficial therapeutic effect in improving glycemic, hepatic and cardiometabolic parameters – The multifaceted effects demonstrated by berberine ursodeoxycholate support this new molecular entity as a unique oral treatment option for T2DM and its comorbidities – T2DM phase 3 data readout is expected to be announced in the first half of 2…

Read Full Article
Medical XpressMedical Xpress

Gut-liver modulator shows promising type 2 diabetes control in phase 2 clinical trial

Researchers across 14 medical centers in China, including Peking University People's Hospital, have found that an investigational drug, berberine ursodeoxycholate (HTD1801), significantly lowered blood sugar levels and improved metabolic and liver health in patients with type 2 diabetes (T2D). The findings and an invited commentary, both published in JAMA Network Open, suggest that HTD1801 could serve as a new oral treatment option for T2D and i…

Read Full Article
American Gastroenterological AssociationAmerican Gastroenterological Association

Optimizing UC care: Insights from the MD3D learning series

Managing ulcerative colitis (UC) can be complex, but the rapidly evolving landscape of treatment options offers hope for improved patient outcomes. Our new four-part learning series, “MD3D: Positioning of new S1P receptor modulators to optimize patient outcomes in ulcerative colitis,” is here to guide you through these advancements with a focus on practical, real-world application.The series offers a comprehensive blend of expert perspectives, c…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

American Gastroenterological Association broke the news in on Tuesday, March 4, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal